Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 4/2015

01-12-2015 | T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

Authors: Jonathan Hebb, Holbrook Kohrt

Published in: Current Hematologic Malignancy Reports | Issue 4/2015

Login to get access

Abstract

The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.
Literature
1.
Gooptu M, Rhoades R, Pro B. Current management of peripheral T-cell lymphomas. Cancer Treat Res. 2015;165:289–303.CrossRefPubMed
2.
Redman JM et al. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015;67(2 Pt A):28–45. 
3.
Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25–34.CrossRefPubMed
4.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 2. 4th ed. Lyon: IARC press; 2008. p. 439.
5.
6.
7.
Younes A et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.CrossRefPubMed
8.••
Pro B et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. This reference is notable for the impressive efficacy with tolerable toxicity for a relatively large sample size of 58 ALCL patients with relapsed refractory disease. Objective response was achieved in 50 (86%), with 33 (57%) complete response (CRs) and 17 (29%) partial responses (PRs).CrossRefPubMed
9.
Gopal AK et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328–34.CrossRefPubMed
10.
11.
Brown MP, Staudacher AH. Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma? Immunotherapy. 2014;6(4):371–5.CrossRefPubMed
12.
Fanale MA et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–43.PubMedCentralCrossRefPubMed
13.
Bartlett N, et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study. J Clin Oncol. 2012;30(suppl; abstr 8027).
14.
Criscuolo M et al. Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin. Br J Haematol. 2015;168(5):617.CrossRefPubMed
15.
Corey K et al. A case of refractory Sezary syndrome with large-cell transformation responsive to brentuximab vedotin. JAMA Dermatol. 2014;150(2):210–2.CrossRefPubMed
16.
Ferenczi K et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405–10.CrossRefPubMed
17.
Ishida T et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494–500.CrossRefPubMed
18.
Ishida T et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.PubMed
19.
20.
Ishii T et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31.CrossRefPubMed
21.
Shinkawa T et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–73.CrossRefPubMed
22.
Yamamoto K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8.CrossRefPubMed
23.
Suzuki R. Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(23):e404-5. author reply e406.CrossRef
24.•
Ishida T et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. This study led to approval of Mogamulizumab in Japan for ATL. Of 26 patients with relapsed ATL, ORR was an impressive 50% with 8 patients achieving CR.CrossRefPubMed
25.
Ogura M et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63.CrossRefPubMed
26.•
Duvic M et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9. This represents the largest trial to date of mogamulizumab in CTCL. ORR in this combined population of previously treated MF and sezary syndrome patients was 37%, and also showed a better response in sezary syndrome (47%) than MF (29%).
27.•
Ishida T et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–82. This is the first published study to show that mogamulizumab could be used effectively in combination with chemotherapy as initial treatment for ATL. RR was better in the mogamulizumab arm (52% CR and 86% ORR, N= 29) compared to chemotherapy alone (33% CR and 75% ORR, N=24), at the cost of increased but manageable toxicity.
28.
Kanazawa T et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014;20(19):5075–84.CrossRefPubMed
29.
Ni X et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and sezary syndrome. Clin Cancer Res. 2015;21(2):274–85.CrossRefPubMed
30.
Taguchi M et al. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient. Ann Hematol. 2015;94(4):693–5.CrossRefPubMed
31.
Ohyama Y et al. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies. Ann Hematol. 2014;93(1):169–71.CrossRefPubMed
32.
Kato K et al. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma. Int J Hematol. 2013;97(3):430–2.CrossRefPubMed
33.
Ifuku H, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. doi:10.​1111/​hepr.​12513.
34.
35.
Zinzani PL et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma. 2012;53(5):789–95.CrossRefPubMed
36.
Jiang L et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173–9.PubMedCentralCrossRefPubMed
37.
Broccoli A et al. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. Clin Lymphoma Myeloma Leuk. 2013;13(4):493–5.CrossRefPubMed
38.
Dearden CE et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721–6.CrossRefPubMed
39.
40.•
Dearden CE et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118(22):5799–802. Alemtuzumab can be administered by intravenous or subcutaneous route. This study demonstrates a huge difference in efficacy in T-PLL depending on route of administration with CR rates up to 90% with IV route as opposed to response rates of 33% when administered subcutaneously.CrossRefPubMed
41.
Enblad G et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–4.CrossRefPubMed
42.
Gallamini A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316–23.CrossRefPubMed
43.
Kim JG et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.CrossRefPubMed
44.
Binder C et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92(11):1521–8.PubMedCentralCrossRefPubMed
45.•
Clark RA et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7. The use of alemtuzumab is limited by significant risk of serious infections. This study is of note because it suggests that low dose alemtuzumab can be effective in leukemic CTCL (but not MF) with less toxicity. This is in contrast to treatment of PLL which requires IV administration for efficacy.PubMedCentralPubMed
46.
de Masson A et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720–4.CrossRefPubMed
47.
Ferrara N et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.CrossRefPubMed
48.
Ganjoo K et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma. 2014;55(4):768–72.PubMedCentralCrossRefPubMed
49.
Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol. 2014;262 Pt A:44–51.CrossRefPubMed
50.
Willenbacher W et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001;112(3):820–3.CrossRefPubMed
51.
Berkowitz JL et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155(2):176–87.PubMedCentralCrossRefPubMed
52.
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–3.CrossRefPubMed
53.
54.
Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16(5):e234–45.CrossRefPubMed
55.
Samimi S et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382–8.PubMedCentralCrossRefPubMed
56.
Kantekure K et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. 2012;34(1):126–8.PubMedCentralCrossRefPubMed
57.•
Lesokhin AM et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014;124(21):291. Although still interim results and small numbers, this is the first data of immune check point inhibition (nivolumab, anti-PD1) in T-cell lymphoma and suggests modest efficacy and safety.
Metadata
Title
Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas
Authors
Jonathan Hebb
Holbrook Kohrt
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 4/2015
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-015-0290-1

Other articles of this Issue 4/2015

Current Hematologic Malignancy Reports 4/2015 Go to the issue

Myeloproliferative Disorders (C Harrison, Section Editor)

Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Molecular Pathogenesis of Peripheral T Cell Lymphoma

Myeloproliferative Disorders (C Harrison, Section Editor)

Current Challenges in Stem Cell Transplantation in Myelofibrosis

Myeloproliferative Disorders (C Harrison, Section Editor)

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Myeloproliferative Disorders (C Harrison, Section Editor)

Immunological Consequences of JAK Inhibition: Friend or Foe?

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits